Cancer Chemotherapy and Pharmacology

, Volume 68, Issue 4, pp 1017–1026 | Cite as

Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting

  • Kyu-Hyoung Lim
  • Tae-Yong Kim
  • Kyung-Hun Lee
  • Sae-Won Han
  • Do-Youn Oh
  • Seock-Ah Im
  • Tae-You Kim
  • Yung-Jue Bang
Original Article

Abstract

Purpose

In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known. The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) in patients with gemcitabine-pretreated pancreatic cancer and to elucidate the prognostic factors.

Methods

Study eligibility was as follows: (1) 18–75 years of age; (2) relapse within 6 months after adjuvant gemcitabine-based chemotherapy (GBC) or previously treated with palliative GBC; and (3) an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2. iFAM consisted of a 5-FU (800 mg/m2) infusion over 10 h on days 1–5, doxorubicin (30 mg/m2) on day 1, and mitomycin-C (8 mg/m2) on day 1 every 4 weeks.

Results

Sixty patients were enrolled. The responses to iFAM included a partial response in 6 patients (10.0%) and stable disease in 8 patients (13.3%). The median progression-free survival (PFS) and overall survival (OS) were 2.4 months (95% confidence interval [CI], 2.0–2.8 months) and 6.1 months (95% CI, 4.2–8.0 months), respectively. The 6- and 12-month survival rates were 50.4 and 26.4%, respectively. Grade 3/4 hematologic toxicities included neutropenia (3.3%) and thrombocytopenia (3.3%). The ECOG PS was a significant prognostic factor for PFS (P < 0.001) and OS (P = 0.022). An elevated CA 19-9 at the time of initiating iFAM (P = 0.011) was a poor prognostic factor for OS.

Conclusions

iFAM is an effective and well-tolerated in patients with gemcitabine-pretreated pancreatic cancer, even patients with an ECOG PS of 2. ECOG PS and CA 19-9 were shown to be significant prognostic factors in this salvage setting.

Keywords

Pancreatic cancer Gemcitabine-pretreated 5-fluorouracil Doxorubicin Mitomycin-C Prognostic factors 

Notes

Conflict of interest

None of the authors have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefGoogle Scholar
  2. 2.
    Cameron JL, Riall TS, Coleman J, Belcher KA (2006) One thousand consecutive pancreaticoduodenectomies. Ann Surg 244:10–15PubMedCrossRefGoogle Scholar
  3. 3.
    Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 189:1–7PubMedCrossRefGoogle Scholar
  4. 4.
    Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMedGoogle Scholar
  5. 5.
    Rocha Lima CM, Savarese D, Bruckner H, Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W, Saville W, Elfring GL, Locker PK, Compton LD, Miller LL, Green MR (2002) Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20:1182–1191PubMedCrossRefGoogle Scholar
  6. 6.
    Heinemann V, Wilke H, Mergenthaler HG, Clemens M, König H, Illiger HJ, Arning M, Schalhorn A, Possinger K, Fink U (2000) Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 11:1399–1403PubMedCrossRefGoogle Scholar
  7. 7.
    Louvet C, André T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 20:1512–1518PubMedCrossRefGoogle Scholar
  8. 8.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966PubMedCrossRefGoogle Scholar
  9. 9.
    Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792PubMedCrossRefGoogle Scholar
  10. 10.
    Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA (2008) Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 113:2046–2052PubMedCrossRefGoogle Scholar
  11. 11.
    Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL (2009) A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 101:1658–1663PubMedCrossRefGoogle Scholar
  12. 12.
    Fortune BE, Li X, Kosuri KV, Weatherby LM, Thomas JP, Bekaii-Saab TS (2009) Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 76:333–337PubMedCrossRefGoogle Scholar
  13. 13.
    Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL (2006) Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 94:481–485PubMedCrossRefGoogle Scholar
  14. 14.
    Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885PubMedCrossRefGoogle Scholar
  15. 15.
    Glimelius B, Hoffman K, Sjödén PO, Jacobsson G, Sellström H, Enander LK, Linné T, Svensson C (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600PubMedGoogle Scholar
  16. 16.
    Smith FP, Hoth DF, Levin B, Karlin DA, MacDonald JS, Woolley PV III, Schein PS (1980) 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46:2014–2018PubMedCrossRefGoogle Scholar
  17. 17.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin. JAMA 253:2061–2067PubMedCrossRefGoogle Scholar
  18. 18.
    Meta-Analysis Group in Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308Google Scholar
  19. 19.
    Meta-Analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 16:3537–3541Google Scholar
  20. 20.
    Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438PubMedCrossRefGoogle Scholar
  21. 21.
    Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91:490–495PubMedCrossRefGoogle Scholar
  22. 22.
    Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT (2009) A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer 45:1589–1596PubMedCrossRefGoogle Scholar
  23. 23.
    Maréchal R, Demols A, Gay F, De Maertelaere V, Arvanitaki M, Hendlisz A, Van Laethem JL (2007) Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology 73:41–51PubMedCrossRefGoogle Scholar
  24. 24.
    Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF (2010) Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 59:1527–1534PubMedCrossRefGoogle Scholar
  25. 25.
    Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopterides P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E (2005) Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 23:369–375PubMedCrossRefGoogle Scholar
  26. 26.
    Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, Mambrini A, Del Freo A, Manni A (2004) Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 67:93–97PubMedCrossRefGoogle Scholar
  27. 27.
    Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell’Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA (2006) Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 94:785–791PubMedCrossRefGoogle Scholar
  28. 28.
    Pelzer U, Kubica K, Stieler J, Schwaner I, Heil G, Görner M, Mölle M, Hilbig A, Dörken B, Riess H, Oettle H (2008) A randomized trial in patients with gemcitabine-refractory pancreatic cancer. Final results of the CONKO 003 study (abstract). J Clin Oncol 26:215sGoogle Scholar
  29. 29.
    MacDonald JS, Woolley PV, Smythe T, Ueno W, Hoth D, Schein PS (1979) 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 44:42–47PubMedCrossRefGoogle Scholar
  30. 30.
    Crooke ST, Bradner WT (1976) Mitoycin C: a review. Cancer Treat Rev 3:121–139PubMedCrossRefGoogle Scholar
  31. 31.
    Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O’Brien M, Tebbutt N, Harrington A, Hill M (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130–3136PubMedCrossRefGoogle Scholar
  32. 32.
    Sartorelli AC, Boothe BA (1965) The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil. Cancer Res 25:1393–1400PubMedGoogle Scholar
  33. 33.
    Schein PS, Lavin PT, Moertel CG (1978) Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer 42:19–22PubMedCrossRefGoogle Scholar
  34. 34.
    Wils J, Bleiberg H, Blijham G, Dalesio O, Duez N, Lacave A, Splinter T (1985) Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 21:191–194PubMedCrossRefGoogle Scholar
  35. 35.
    Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M (2007) Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37:114–120PubMedCrossRefGoogle Scholar
  36. 36.
    Magistrelli P, Antinori A, Crucitti A, La Greca A, Masetti R, Coppola R, Nuzzo G, Picciocchi A (2000) Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 74:36–40PubMedCrossRefGoogle Scholar
  37. 37.
    Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59:296–301PubMedCrossRefGoogle Scholar
  38. 38.
    Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA (2005) Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 93:195–199PubMedCrossRefGoogle Scholar
  39. 39.
    Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D (2005) CA 19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93:740–743PubMedCrossRefGoogle Scholar
  40. 40.
    Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IG (2003) Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89:1413–1417PubMedCrossRefGoogle Scholar
  41. 41.
    Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313–5327PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kyu-Hyoung Lim
    • 1
    • 2
  • Tae-Yong Kim
    • 1
  • Kyung-Hun Lee
    • 1
  • Sae-Won Han
    • 1
    • 3
  • Do-Youn Oh
    • 1
    • 3
  • Seock-Ah Im
    • 1
    • 3
  • Tae-You Kim
    • 1
    • 3
  • Yung-Jue Bang
    • 1
    • 3
  1. 1.Department of Internal MedicineSeoul National University Hospital, Seoul National University College of MedicineSeoulKorea
  2. 2.Department of Internal MedicineKangwon National University HospitalGangwon-doKorea
  3. 3.Cancer Research InstituteSeoul National University College of MedicineSeoulKorea

Personalised recommendations